Coronary Microvascular Disease (CMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Coronary microvascular disease (CMD) is a group of disorders that affect the structure and function of coronary microcirculation. CMD is prevalent in patients with various cardiovascular risk factors and is associated with an increased risk of adverse events. Several potential causes for microvascular dysfunction have been identified, including cardiovascular risk factors, impaired vasodilatation capacity, and endothelium-dependent and endothelium-independent mechanisms. Patients with CMD may have chest pain that can persist even after cessation of activity. CMD is divided into four major categories: (1) CMD in the absence of coronary artery and myocardial disease, (2) CMD in the presence of myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, hypertension, aortic stenosis, and infiltrative heart disease, (3) CMD in the presence of obstructive coronary artery diseases such as stable coronary artery disease and acute coronary syndromes, and (4) iatrogenic dysfunction seen in instances of distal emboli that form because of coronary recanalization. Although coronary flow reserve is similar in men and women with CMD, women are reported to have dysfunction three times more likely than men.
Thelansis’s “Coronary Microvascular
Disease (CMD) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2022 To 2032" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Coronary Microvascular Disease
(CMD) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Coronary Microvascular Disease (CMD) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Coronary Microvascular Disease (CMD) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment